Most Read Articles
Yesterday
The effectiveness of programmed cell death protein 1 or its ligand (L1) inhibitors is similar as regards time to initiation of third therapy or death and overall survival in patients with platinum refractory locally advanced/unresectable or metastatic urothelial carcinoma, a recent study has shown.

Podcast: Associate Prof Pilar Garrido says osimertinib may be the best option in the first-line treatment of advanced NSCLC based on FLAURA OS results.

02 Dec 2019
Podcast: Associate Prof Pilar Garrido says osimertinib may be the best option in the first-line treatment of advanced NSCLC based on FLAURA OS results.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
The effectiveness of programmed cell death protein 1 or its ligand (L1) inhibitors is similar as regards time to initiation of third therapy or death and overall survival in patients with platinum refractory locally advanced/unresectable or metastatic urothelial carcinoma, a recent study has shown.